FDA staff backs Medicines Co's once-rejected blood clot preventer

April 13, 2015 12:26 PM

11 0

April 13 (Reuters) - An intravenous blood clot preventer developed by The Medicines Co should be approved by the U.S. Food and Drug Administration, FDA staff reviewers concluded.

The injection, cangrelor, which won European approval in March, is designed to prevent blood clots during angioplasty, a procedure to widen narrow or clogged coronary arteries, which often includes the use of stents.

Also read: FDA approves expanded use of AstraZeneca cancer drug

Read more

To category page